Immuno-Oncology pioneer ImmVue Therapeutics to adopt Enki™ Lead Generator to discover first-in-class cancer drugs. VANCOUVER, BC – Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug… Read More
First point of contact for partners seeking to manufacture cell culture-based therapies more efficiently Draws on multidisciplinary team of experts Drives the development of system solutions to address upstream challenges… Read More
VICTORIA, BC – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with… Read More
Beazley, the leading specialty insurer, has announced Paul Bantick as Chief Underwriting Officer, following the decision by Bob Quane to retire. Mr Bantick will report to Adrian Cox, CEO of Beazley,… Read More
The Terry Fox Research Institute (TFRI) recently made updates to its Board of Directors. Dr. John Bell, a driving force in the development of virus-based cancer therapies and longtime TFRI… Read More
